Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Bluebird Bio Presents Promising Results for Gene Therapy in Rare Blood Disorder
Bluebird Bio Presents Promising Results for Gene Therapy in Rare Blood Disorder
Bluebird Bio Presents Promising Results for Gene Therapy in Rare Blood Disorder
Submitted by
CP Staff
on June 15, 2018 - 10:01am
Source:
CP Wire
News Tags:
Bluebird Bio
gene therapy
LentiGlobin
beta thalassemia
sickle cell disease
Headline:
Bluebird Bio Presents Promising Results for Gene Therapy in Rare Blood Disorder
snippet:
One time treatment may address underlying cause of the disease
Works by inserting a functional human beta-globin gene into a patient’s own hematopoietic stem cells
Evaluating LentiGlobin in both β-thalassemia and Sickle Cell Disease
LentiGlobin granted orphan drug status in both β-thalassemia and Sickle Cell Disease
Do Not Allow Advertisers to Use My Personal information